These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Delayed renal excretion of methotrexate after a severe anaphylactic reaction to methotrexate in a child with osteosarcoma. Ozguven AA; Uysal K; Gunes D; Koroglu T; Gurcu O; Olgun N J Pediatr Hematol Oncol; 2009 Apr; 31(4):289-91. PubMed ID: 19346884 [TBL] [Abstract][Full Text] [Related]
4. A population pharmacokinetic/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma. Johansson ÅM; Hill N; Perisoglou M; Whelan J; Karlsson MO; Standing JF Ther Drug Monit; 2011 Dec; 33(6):711-8. PubMed ID: 22105588 [TBL] [Abstract][Full Text] [Related]
5. A greenstick osteoporotic tibial fracture while on chemotherapy in a 12-year-old girl with osteosarcoma of the knee: does a preventive role exist for agents that reduce iatrogenic bone loss and skeletal-related events? Zoccali C; Chichierchia G; Prencipe U; Nuzzo C; Anelli V; Ferraresi V J Biol Regul Homeost Agents; 2011; 25(1):131-5. PubMed ID: 21382282 [TBL] [Abstract][Full Text] [Related]
6. Outpatient high-dose methotrexate: proceed with extreme caution, if at all. Womer RB Pediatr Blood Cancer; 2010 Dec; 55(7):1250-1. PubMed ID: 20981687 [No Abstract] [Full Text] [Related]
7. The correlation between dose of folinic acid and neurotoxicity in children and adolescents treated for osteosarcoma with high-dose methotrexate (HDMTX): a neuropsychological and psychosocial study. Bonda-Shkedi E; Arush MW; Kaplinsky C; Ash S; Goshen Y; Yaniv I; Cohen IJ J Pediatr Hematol Oncol; 2013 May; 35(4):271-5. PubMed ID: 23612378 [TBL] [Abstract][Full Text] [Related]
8. Risk factors associated with delayed methotrexate clearance and increased toxicity in pediatric patients with osteosarcoma. Young EP; Cheng WS; Bernhardt MB; Wang LL; Rainusso N; Foster JH Pediatr Blood Cancer; 2020 Apr; 67(4):e28123. PubMed ID: 31867853 [TBL] [Abstract][Full Text] [Related]
9. Ambulatory high-dose methotrexate administration among pediatric osteosarcoma patients in an urban, underserved setting is feasible, safe, and cost-effective. Mahadeo KM; Santizo R; Baker L; Curry JO; Gorlick R; Levy AS Pediatr Blood Cancer; 2010 Dec; 55(7):1296-9. PubMed ID: 20949591 [TBL] [Abstract][Full Text] [Related]
10. Anaphylactoid reaction to high-dose methotrexate and successful desensitization. Oulego-Erroz I; Maneiro-Freire M; Bouzón-Alejandro M; Vázquez-Donsión M; Couselo JM Pediatr Blood Cancer; 2010 Sep; 55(3):557-9. PubMed ID: 20533520 [TBL] [Abstract][Full Text] [Related]
11. [High-dose methotrexate and cerebral neurotoxicity. Apropos of a case of arachnoiditis]. Brain E; Alexandre J; Minozzi C; Misset JL Presse Med; 1997 Mar; 26(6):265-8. PubMed ID: 9122123 [TBL] [Abstract][Full Text] [Related]
12. [A case of subacute transient cerebral dysfunction in a osteosarcoma patient following high-dose methotrexate]. Yamada K; Takahashi M; Yoshida M Gan To Kagaku Ryoho; 2002 Mar; 29(3):469-72. PubMed ID: 11915742 [TBL] [Abstract][Full Text] [Related]
13. Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma. Mir O; Ropert S; Babinet A; Alexandre J; Larousserie F; Durand JP; Enkaoua E; Anract P; Goldwasser F Cancer Chemother Pharmacol; 2010 Nov; 66(6):1059-63. PubMed ID: 20155268 [TBL] [Abstract][Full Text] [Related]
14. Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression. Patiño-García A; Zalacaín M; Marrodán L; San-Julián M; Sierrasesúmaga L J Pediatr; 2009 May; 154(5):688-93. PubMed ID: 19159907 [TBL] [Abstract][Full Text] [Related]
15. Osteoporosis in children and young adults: a late effect after chemotherapy for bone sarcoma. Pirker-Frühauf UM; Friesenbichler J; Urban EC; Obermayer-Pietsch B; Leithner A Clin Orthop Relat Res; 2012 Oct; 470(10):2874-85. PubMed ID: 22806259 [TBL] [Abstract][Full Text] [Related]
16. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Crews KR; Liu T; Rodriguez-Galindo C; Tan M; Meyer WH; Panetta JC; Link MP; Daw NC Cancer; 2004 Apr; 100(8):1724-33. PubMed ID: 15073863 [TBL] [Abstract][Full Text] [Related]
17. Preoperative administration of high-dose methotrexate for osteosarcoma. Chan KW; Knowling MA; Duncan CP; Morton KS Can J Surg; 1984 May; 27(3):305-7, 309. PubMed ID: 6586272 [TBL] [Abstract][Full Text] [Related]
18. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068 [TBL] [Abstract][Full Text] [Related]
19. Interaction between methotrexate and ciprofloxacin. Dalle JH; Auvrignon A; Vassal G; Leverger G J Pediatr Hematol Oncol; 2002 May; 24(4):321-2. PubMed ID: 11972105 [TBL] [Abstract][Full Text] [Related]